Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below Fifty Day Moving Average – Here’s Why

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $3.92 and traded as low as $3.80. Voyager Therapeutics shares last traded at $3.96, with a volume of 462,509 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on VYGR shares. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, March 17th. Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Truist Financial upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Price Performance

The company has a market cap of $236.02 million, a PE ratio of -1.95 and a beta of 1.38. The business’s 50 day moving average price is $3.92 and its 200-day moving average price is $4.18.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. The business had revenue of $13.46 million during the quarter, compared to the consensus estimate of $10.49 million. Equities analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 11,511 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $3.87, for a total transaction of $44,547.57. Following the completion of the sale, the chief executive officer directly owned 472,549 shares in the company, valued at $1,828,764.63. This trade represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,294 shares of company stock worth $233,241 in the last three months. 6.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of VYGR. EcoR1 Capital LLC increased its holdings in Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after purchasing an additional 3,332,544 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Voyager Therapeutics by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock valued at $15,178,000 after buying an additional 40,147 shares during the last quarter. Opaleye Management Inc. acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth approximately $4,704,000. Erste Asset Management GmbH grew its position in shares of Voyager Therapeutics by 7.0% during the fourth quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock worth $4,718,000 after buying an additional 78,348 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Voyager Therapeutics by 1.1% in the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock worth $3,474,000 after buying an additional 11,929 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.